☆ 4.7 Article

Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status

SCIENTIFIC REPORTS (2022)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Hemorrhage Risk Profiles among Different Antithrombotic Regimens: Evidence from a Real-World Analysis of Postmarketing Surveillance Data

Xue Sun et al.

Summary: This study analyzed data from the FDA and found that different antithrombotic regimens have varying risks of hemorrhage complications. Betrixaban monotherapy showed the highest association with bleeding, while the combination therapy of clopidogrel plus new oral anticoagulants had higher bleeding risks.

CARDIOVASCULAR DRUGS AND THERAPY (2022)

Add to Collection

Review Medicine, Research & Experimental

Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review

Molly Murton et al.

Summary: The review included ten observational studies with participants ranging from 3033 to 46,949, conducted in countries such as the USA, China, France, Italy and Spain. The prevalence of CKD ranged from 2% to 17%, with comorbidities increasing with albuminuria severity, indicating a higher burden of disease in high-risk and very high-risk groups according to the KDIGO 2012 classification. New studies framed by the KDIGO 2012 classification are needed to address key gaps in the understanding of CKD burden and outcomes.

ADVANCES IN THERAPY (2021)

Add to Collection

Article Urology & Nephrology

Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study

Nisha Bansal et al.

Summary: In chronic kidney disease (CKD), increases in NT-proBNP were significantly associated with greater risk of incident HF and AF, and increases in sST2 were associated with HF. Further studies should investigate whether these markers of subclinical cardiovascular disease can be modified to reduce the risk of cardiovascular disease in CKD.

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

Add to Collection

Article Urology & Nephrology

CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treatead with Apixaban Versus Warfarin

James B. Wetmore et al.

Summary: By comparing kidney disease progression among patients treated with direct oral anticoagulants (DOACs) versus warfarin, the study found that apixaban may be associated with a lower risk of progression of chronic kidney disease (CKD) and does not increase the risk of developing incident kidney failure compared to warfarin in patients with atrial fibrillation.

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

Add to Collection

Review Medicine, General & Internal

Integrated care and outcomes in patients with atrial fibrillation and comorbidities

Marco Proietti et al.

Summary: In high-risk atrial fibrillation patients with diabetes mellitus, chronic kidney disease, and metabolic syndrome, adherent management to the ABC pathway was associated with a lower risk of composite outcomes including cardiovascular events, cardiovascular death, and all-cause death.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, General & Internal

Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs 'real-world'

Wern Yew Ding et al.

Summary: In this study, AF patients with CKD treated with vitamin K antagonists were found to have significantly higher rates of major adverse events in the real-world cohort compared to the AMADEUS trial cohort. The risk of adverse events, including major bleeding and all-cause mortality, remained significantly higher in the real-world cohort even after multivariable adjustment.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2021)

Add to Collection

Review Medicine, General & Internal

Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy

Michele Magnocavallo et al.

Summary: AF and CKD are closely related, with AF prevalence being high in advanced CKD stages. ESRD patients with AF have a higher mortality rate due to increased stroke incidence and elevated bleeding risk. The use of DOAC therapy in CKD patients, especially in ESRD patients, needs further exploration.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis

Chen Chen et al.

Summary: The study quantified the benefit-risk profiles of rivaroxaban or apixaban versus warfarin in non-valvular atrial fibrillation patients with severe chronic kidney disease (CKD) or on dialysis. Current evidence suggests that rivaroxaban or apixaban are safe and at least as effective as warfarin in this patient population.

CARDIOVASCULAR DRUGS AND THERAPY (2021)

Add to Collection

Article Pharmacology & Pharmacy

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations

Veronica Ashton et al.

Summary: Rivaroxaban is an oral anticoagulant approved for multiple indications, including cardiovascular diseases, for patients with renal impairment. Evaluation of kidney function is important when using rivaroxaban to ensure its safety and effectiveness in treatment.

JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Atrial Fibrillation

Gregory F. Michaud et al.

Summary: A 63-year-old healthy male with atrial fibrillation presents with symptoms of dyspnea and irregular heartbeat. Physical examination reveals high blood pressure, irregular pulse, and ECG confirms atrial fibrillation. Further evaluation and treatment plan are needed.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Hematology

Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis

Mohammad Alhousani et al.

Summary: DOACs and other anticoagulants did not show statistical difference in preventing recurrent VTEs among CKD patients. DOACs had significantly lower risk of major and non-major clinically relevant bleeding compared to VKA, regardless of renal impairment level. There was no difference in risk of intracranial bleeding between DOACs and VKAs.

THROMBOSIS RESEARCH (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Direct Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure

Evan M. White et al.

Summary: Direct oral anticoagulants may be a safe and effective alternative to warfarin for the treatment of venous thromboembolism and atrial fibrillation in obese patients, elderly patients, and patients with chronic kidney disease.

CURRENT CARDIOLOGY REPORTS (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Chronic Kidney Disease and Cardiovascular Disease: A Personalized Approach

Ashton C. Lai et al.

Summary: Cardiovascular disease is the leading cause of death in end-stage renal disease patients, exacerbated by dialysis treatment. Multimodality imaging may offer additional prognostication and risk stratification for these patients.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Review Hematology

A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation

Nathan R. Hill et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2020)

Add to Collection

Article Multidisciplinary Sciences

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France

Kevin Bowrin et al.

PLOS ONE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Acute kidney injury in heart failure: a population study

Jose Luis Holgado et al.

ESC HEART FAILURE (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation A Systematic Review and Meta-Analysis

Aya F. Ozaki et al.

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2020)

Add to Collection

Review Medicine, General & Internal

Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies

Larisa Anghel et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events

Wern Yew Ding et al.

AMERICAN JOURNAL OF CARDIOLOGY (2020)

Add to Collection

Article Economics

Use of real-world evidence in meta-analyses and cost-effectiveness models

Kevin Bowrin et al.

JOURNAL OF MEDICAL ECONOMICS (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials

Magdalena Domek et al.

EUROPEAN HEART JOURNAL SUPPLEMENTS (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience

Zbigniew Heleniak et al.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

Direct Oral Anticoagulants vs. Vitamin-K Antagonists in the Elderly With Atrial Fibrillation: A Systematic Review Comparing Benefits and Harms Between Observational Studies and Randomized Controlled Trials

Nan-Nan Shen et al.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Stroke prevention in atrial fibrillation: comparison of recent international guidelines

Tze-Fan Chao et al.

EUROPEAN HEART JOURNAL SUPPLEMENTS (2020)

Add to Collection

Article Multidisciplinary Sciences

The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis

Oh Young Bang et al.

PLOS ONE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical Outcomes of Warfarin Initiation in Advanced Chronic Kidney Disease Patients With Incident Atrial Fibrillation

Manyoo A. Agarwal et al.

JACC-CLINICAL ELECTROPHYSIOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease A Systematic Review and Meta-analysis

Mandeep S. Randhawa et al.

JAMA NETWORK OPEN (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

Craig T. January et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation

Jean-Baptiste Briere et al.

CURRENT MEDICAL RESEARCH AND OPINION (2019)

Add to Collection

Review Urology & Nephrology

Anticoagulant-related nephropathy: systematic review and meta-analysis

Karolinny Borinelli de Aquino Moura et al.

CLINICAL KIDNEY JOURNAL (2019)

Add to Collection

Article Critical Care Medicine

Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report

Gregory Y. H. Lip et al.

CHEST (2018)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Atrial fibrillation hospitalization, mortality, and therapy

Roy M. John et al.

EUROPEAN HEART JOURNAL (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis

Hans Van Der Meersch et al.

AMERICAN HEART JOURNAL (2017)

Add to Collection

Article Critical Care Medicine

Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease A Meta-Analysis of Observational Studies

Khagendra Dahal et al.

CHEST (2016)

Add to Collection

Article Critical Care Medicine

A Prospective Study of Estimated Glomerular Filtration Rate and Outcomes in Patients With Atrial Fibrillation

Amitava Banerjee et al.

CHEST (2014)

Add to Collection

Article Cardiac & Cardiovascular Systems

Net Clinical Benefit of Antithrombotic Therapy in Patients With Atrial Fibrillation and Chronic Kidney Disease A Nationwide Observational Cohort Study

Anders Nissen Bonde et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

Add to Collection

Review Cardiac & Cardiovascular Systems

Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?

Gregory Y. H. Lip

EUROPEAN HEART JOURNAL (2013)

Add to Collection

Article Medicine, General & Internal

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey et al.

ANNALS OF INTERNAL MEDICINE (2009)

Add to Collection

Article Urology & Nephrology

Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients

Kevin E. Chan et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.